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Purposed Usage in Calves Showing Symptoms of Respiratory Tract Infection 
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ABSTRACT
Background: Respiratory tract diseases are commonly seen in beef cattle. Young calves are affected with many respira-
tory pathogens. Viral pathogens are particularly seen. There are many causative factors, e.g. environmental conditions, 
immune system of calves. Therefore, alternative treatments are needed for viral respiratory infections. The purpose of the 
current study was to investigate effectiveness of Umckaloabo/EPs®7630 liquid extract in some bovine viral pathogens of 
young beef calves.
Materials, Methods & Results: Antibody presence in terms of bovine herpesvirus type 1 (BHV-1), bovine viral diar-
rhea virus (BVDV), bovine parainfluenza virus type 3 (BPIV-3), bovine respiratory syncytial virus (BRSV) and bovine 
adenovirus type 3 (BAV-3) was searched in blood serum samples of 40 Holstein calves aged 6 months and over showing 
respiratory tract infection symptoms. All animals were found seronegative in terms of other factors except BRSV. Out 
of 20 BRSV seropositive calves, 10 of them were classified as control group and the other ten as testing group. BRSV 
antibody titers were also detected in blood samples of both groups on day 0. Umckaloabo/EPs®7630 liquid extract was 
given through oral route to animals in testing group according to their weights for 14 days morning, noon and night. No 
application was performed on animals in control group. BRSV antibody titers were detected in blood samples of animals 
in both groups taken on days 1st, 3rd, 5th, 7th, 10th and 14th. At the end of day 14th, BRSV antibody titer increased in 9 
out of 10 animals (90%) in testing group that were given Umckaloabo/EPs® 7630 liquid extract while one of them (10%) 
showed no variability. BRSV antibody titer increased in 6 out of 10 animals (60%) in control group while it decreased in 
one of them (10%) and 3 of them (30%) showed no variability. In testing group, BRSV antibody titer started to increase 
on day 3rd in 6 out of 10 animals (60%), on day 5th in one (10%), on day 10th in one (10%) and on day 14th in another 
(10%). In control group, BRSV antibody titer started to increase on day 3rd in 3 out of 10 animals (30%) and on day 5th 
in 3 of them (30%). When haematologic values of blood samples taken from animals in testing and control groups on day 
14th were studied comparatively, no statistical importance (P < 0.01 or P < 0.05) and difference was detected. As a result, 
in stock calves showing respiratory tract infection symptoms, applying Umckaloabo/EPs® 7630 liquid extract helped BRSV 
antibody titer to increase and symptoms decreased. The increase in antibody titers started from day 3rd especially after 
applying Umckaloabo/EPs® 7630 liquid extract. 
Discussion: Respiratory system infections are contagious and fatal in calves. Respiratory tract bacterial and viral vaccina-
tions are applied in order to prevent losses of calves due to these problems. However, these vaccinations are not sufficient 
most of the time and antibiotics+supportive treatment applications follow afterwards. Therefore, we advise to use a herbal 
product, Umckaloabo/ EPs®7630 liquid extract, that has both an antiviral efficiency and a feature of supporting immune 
system in order to prevent mortalities in stock calves, to stop the infection from spreading on all the herd and to decrease 
the symptoms of respiratory system. We believe that the obtained data should be supported with more examples and more 
wide-ranging studies. 
Keywords: respiratory infection, BRSV, Umckaloabo/ EPs®7630, Pelargonium sidoides, calf.
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INTRODUCTION
Respiratory tract problems in cattle settled in 
plants can be caused by many pathogens [19]. Espe-
cially viral pathogens are the most commonly seen 
factors [20]. BRSV has an important place among 
pneumonic cases seen in cattle. It is frequently seen 
especially in calves and calves younger than 1 year. 
In calves younger than six months, it causes acute 
interstitial pneumonia proceeding with alveolitis and 
bronchiolitis [26].
Pelargonium sidoides (PS) is a kind of plant 
used traditionally by native people in coastal areas 
of South Africa. The extract from the root of PS is 
a medicine whose effectiveness has been proven by 
various fitomedical studies (in vitro, in vivo and clini-
cal). PS contains phenolic and cinnamic acids, tannins, 
flavonoids and coumarins. Towards the end of the 20th 
century, an effective and reliable herbal medicine called 
Umckaloabo was developed to cure acute bronchitis 
especially in children and to cure infections of up-
per respiratory tract obstructions [11]. Umckaloabo 
(EPs®7630) is an ethanolic root extract of PS roots [4] 
and its antibacterial, antiviral and immunomodulator 
features have been revealed by many studies and its 
therapeutic effects were determined. 
This medicine is generally used for upper 
respiratory tract infections in human medicine [2,6]. 
The medicine was proved to be effective for microor-
ganisms and immune systems [10,13], by every ex-
perimental, observational and clinical study performed 
with PS and its extracts.  However, there is no study on 
its usage in veterinary medicine. In this regard, deeper 
knowledge and research are needed on the effectiveness 
of PS and its extracts for diseases both in veterinary 
and human medicine. 
MATERIALS AND METHODS
Animals and properties of the management
In this study, we worked between 2015 and 
2016 years in a stock cattle farming plant located in 
central Burdur Kışla district in Turkey. In this man-
agement, we worked on 40 Holstein calves aged 6-8 
months old (weighing between 120-200 kg) showing 
respiratory system symptoms (cough, 40-41°C fever, 
inappetency, serious nasal flow, drying in nasolabial 
area, increase in respiratory rate, foamy nasal flow and 
dyspnea) depending on acute and peracute proceeding 
pneumonia. Symptoms of animals were determined 
by plant veterinary surgeon by getting help. The plant 
the study was applied was semi-outdoor with linoleum 
ceiling, brick side walls and soil ground. The animals 
were always in contact in three different sections (120 
kg, 150 kg, 180-200 kg) seperated by iron paddocks. 
There was a feedbox and a waterbowl in each section. 
Within the plant, adult stock cattle were located in 
another area 200 meters away. During the study, no 
practice of vaccination or antibiotics was applied on 
testing and control group animals used in the study. 
The fact that the animals had no vaccination for bovine 
herpesvirus type 1 (BHV-1), bovine viral diarrhea virus 
(BVDV), bovine parainfluenza virus type 3 (BPIV-3), 
bovine respiratory syncytial virus (BRSV) and bovine 
adenovirus type 3 (BAV-3) before the study was con-
firmed by getting information from plant veterinary 
surgeon. 
Blood sampling of animals to be used in the study
In the study, blood samples taken from 
v. jugularis of calves showing respiratory system symp-
toms (those under treatment and control groups) were 
collected in 10 mL sterile vacuum tubes1 containing 
no chemical substances. Blood samplings of BRSV 
seropositive animals (testing and control groups) were 
taken on days 1st, 3rd, 5th, 7th, 10th and 14th. Samples 
were taken to lab with cold chain and centrifuged at 
720 g in due form. The obtained serum samples were 
taken into eppendorf tubes2 and tested within the same 
day. Besides, blood samples of the same animals were 
collected in 8 mL EDTA sterile vacuum tubes1 on day 
14th in order to detect whether there were changes in 
haematological parameters. 
Applying Umckaloabo/ EPs®7630 liquid extract on ani-
mals to be used in the study
In the study, Umckaloabo/ EPs®7630 liquid 
extract Umca solution3 was used. The compound of 
this commercial liquid extract includes 80 g of PS 
root liquid extract as the active substance per 100 g 
of solution and ethanol and glycerol as dissolver and 
protector. Commercial introduction of Umca solution 
includes 20 and 50 mL self-dropping glass bottles. 
In our study, the usage of Umca solution in 
calves was determined by considering the average 
adult human weight. Around the world, the average 
adult human weight was found as 62.0 kg (condensed 
between 58.8 and 74.6) [27] and this figure was ac-
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cepted as 60 kg. Accordingly, we applied 60 drops of 
Umca solution for calves weighing 120 kg, 75 drops for 
those weighing 150 kg and 90 drops for those weigh-
ing between 180-200 kg. Human beings are advised 
to consume Umca solution by dropping it into some 
amount of water. In the study, standard amount (100 
mL) of sterilized distilled water was used. 
In the study, for calves showing respiratory 
system symptoms and found BRSV seropositive in 
their blood serum samples, morning, noon and night 
between days 1st-14th, Umckaloabo/ EPs®7630 com-
mercial liquid extract was homogenized in plastic 
containers and applied through oral route by injectors 
as 60 drops in 100 mL water for calves weighing 120 
kg (Testing 1, Testing 2, Testing 3), 75 drops in 100 
mL water for those weighing 150 kg (Testing 4, Testing 
5, Testing 6) and 90 drops in 100 mL water for those 
weighing between 180-200 kg (Testing 7, Testing 8, 
Testing 9). No treatment application was performed 
for animals in control group (Control 1-10).
ELISA (blood)-Serological diagnostic method of respira-
tory tract infections
Respiratory ELISA kit4 commercial testing 
product was used in order to detect antibody presence 
in the plant against BHV-1, BVDV, BRSV, BPIV-3 
and BAV-3 in blood serum samples taken on day 1st 
from 40 stock calves showing respiratory system 
symptoms. The application was performed according 
to kit procedure.
ELISA (blood)-Calculating antibody titers with BRSV IgG
Twenty BRSV seropositive calves were clas-
sified as 10 for control group and 10 for testing group 
using Respiratory ELISA kit4 commercial testing 
product. In blood samples of both groups taken on 
days 1st, 3rd, 5th, 7th, 10th and 14th, BRSV titers were 
detected using BRSV IgG Antibody Test Kit5. Blood 
samples were diluted with sterile saline solution at a 
rate of 1/2 according to log2 base. Except for negative 
and positive controls, dilutions for each sample were 
performed within 8 compartments of the plate at rates 
of 1/2, 1/4, 1/8, 1/16, 1/32, 1/64, 1/128, 1/256. Other 
stages of the application were carried out according 
to kit procedure.
Determining haematological parameters
Blood samples taken into K3EDTA tubes on 
day 14th from BRSV seropositive calves classified as 
10 for testing and 10 for control groups were examined 
by full blood device6 for haematological studies. 
Statistical analysis
In this study, 2 sample t-test analysis was per-
formed to compare haematological parameters between 
testing and control groups. The analysis was carried out 
using Minitab7 programme. Values smaller than P < 
0.01 or P < 0.05 were statistically considered important.
RESULTS
Respiratory system symptoms of animals
In the study, respiratory system symptoms in 10 
Holstein calves within the control group continued and 
subsided slightly. Respiratory system symptoms in 10 
Holstein calves within the testing group subsided and 
got better. Respiratory system symptoms of animals 
were determined by the help of plant veterinary surgeon. 
ELISA (blood) - Serological diagnostic results of respira-
tory tract infections
Antibody presence in the plant against BHV-
1, BVDV, BRSV, BPIV-3 and BAV-3 in blood serum 
samples taken on day 0. from 40 stock calves show-
ing respiratory system symptoms was examined. All 
samples were found as BRSV seropositive while other 
factors were found seronegative in terms of BHV-1, 
BVDV, BPIV-3 and BAV-3. 
ELISA (blood)-Calculating antibody titers with BRSV IgG 
in testing and control groups
Twenty BRSV seropositive calves were classi-
fied as 10 for testing and 10 for control groups. BRSV 
titers were detected in blood samples taken from both 
groups on days 1st, 3rd, 5th, 7th, 10th and 14th (Tables 1 
and 2). Blood samples were diluted at a rate of ½ accord-
ing to log2 base. Except for negative and positive con-
trols, dilutions for each sample were performed within 8 
compartments of the plate at rates of 1/2, 1/4, 1/8, 1/16, 
1/32, 1/64, 1/128, 1/256. At the end of day 14th, in 9 out 
of 10 animals in testing group (90%) that were given 
Umckaloabo/ EPs®7630 liquid extract, BRSV antibody 
titer increased and no change was observed in one of 
them (10%). In 6 out of 10 animals (60%) in control 
group, BRSV antibody titer increased, no change was 
observed in three of them (30%) and it decreased in one 
of them (10%). In testing group, BRSV antibody titer 
started to increase in 6 out of 10 animals (60%) on day 
3rd, in 1 of them (10%) on day 5th, in 1 of them (10%) 
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on day 10th and in one of them (10%) on day 14th. In 
control group, BRSV antibody titer increased in 3 out 
of 10 animals (30%) on day 3rd. and in 3 of them (30%) 
on day 5th (Tables 1 and 2).
Haematological parameter results
When haematological values (WBC, LYM, 
MID, GRA, LY%, MI%, GR%, RBC, HGB, HCT, 
MCV, MCH, MCHC, PLT) in blood samples taken on 
day 14th from animals in testing and control groups 
were comparatively studied, no statistical importance 
(P < 0.01 or P < 0.05) or difference was detected 
between both groups (Tables 3 and 4) (Table 5). In 
brief, the possibility of averages between both groups 
to be different from each other was found higher than 
1% and 5%. 
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BRSV played the biggest role in respiratory 
system epidemics in calves in 20 herds located in 
Middle and Southeast France [24]. Similarly, BRSV 
and BPIV-3 factors were regarded responsible for 
respiratory infection epidemics in calves in Ireland 
[5]. Within naturally developed infections in BRSV 
endemic areas, the infection mostly develop in calves 
smaller than 6 months old and adult animals become 
immune. However, together with virus introduction 
into areas where BRSV non-endemic and BRSV sero-
negative adult animals are located, animals of all ages 
might become infected [8,25].
On our day, when vaccinations against RSV 
infections are not available, some treatment applica-
tions that have moderate or limited efficiency such as 
palivizumab (monoclonal antibody against RSV fu-
sion protein) and ribavirin (nucleoside analogue) can 
be performed. That’s why developing a new antiviral 
medicine against RSV infections is needed. In this 
regard, some herbal origin natural products as an anti-
RSV activity have been developed. Among these herbs, 
especially tannin substances incativate RSV particles 
and prevent the virus from binding and entering into 
the cell including fusion stages. Therefore, respira-
tory system symptoms resulting from RSV, including 
inflammations in respiratory tracts, can be cured by 
some natural herbal products [12]. Applications of 
herbal origin medicine on many respiratory system 
infections to this day have been performed on humans 
and experimental animals. About this topic, no study is 
available on calves and cattle. That’s why our results 
from the study were mostly evaluated and compared 
with data obtained from people.
In our study, at the end of day 14th, in 9 out 
of 10 animals in testing group (90%) that were given 
Umckaloabo/ EPs®7630 liquid extract, BRSV antibody 
titer increased and no change was observed in one of 
them (10%). In 6 out of 10 animals (60%) in control 
group, BRSV antibody titer increased, no change was 
observed in three of them (30%) and it decreased in 
one of them (10%). In testing group, BRSV antibody 
titer started to increase in 6 out of 10 animals (60%) on 
day 3rd, in 1 of them (10%) on day 5th, in 1 of them 
(10%) on day 10th and in one of them (10%) on day 
14th. In control group, BRSV antibody titer increased 
in 3 out of 10 animals (30%) on day 3rd and in 3 of 
them (30%) on day 5th. In case of naturally developed 
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BRSV infection in calves aged 6-7 months old, IgM 
and IgG antibody titers increased. In case of natural 
infections based on the respiratory system developing 
during acute period especially in calves, IgM and IgG 
respond improved [28]. PS extracts were confirmed 
by some testing to have displayed decent activations 
towards influenza viruses (H1N1 and H3N2), cox-
sackie A9 virus, human coronavirus, RSV, PI-3, HSV-1 
and 2 [15,17,22]. These two research groups [15,22] 
emphasized that EPs®7630 extract was more active 
for membranous viruses rather than non-membranous 
ones. Michaelis et al. [15] searched the effectiveness 
of EPs®7630 extract in replication of respiratory vi-
ruses. In the study, EPs®7630 extract was practised on 
adenovirus 3 and 7, RSV, human rhinovirus 16, H1N1 
and H3N2 influenza, coronavirus (HCO-229E) and 
coxsackie virus A9. EPs®7630 was determined to have 
interfered with cytopathogenic effect (CPE) caused by 
RSV, coronavirus, H1N1 and H3N2 influenza, parain-
fluenza type 3 (PI-3) and coxsackie virus A9. Besides, 
effects of EPs®7630 on H1N1 and H3N2 influenza, 
RSV, coronavirus (HCO-229E), PI-3 and coxsackie 
virus A9 titers were studied and EPs®7630 was found 
to have caused a decrease in all sensitive virus titers 
depending on the dosage. In our study, after day 14th, 
antibody titer of the testing group given Umckaloabo/
EPs®7630 liquid extract was found higher than the 
control group given no extract. In addition, on day 
3rd, antibody increase was most detected in animals 
in testing group. 
Gezer and Turan [9] studied the effects of add-
ing geranium root (PS) extract to fishmeal at varying 
rates on growth of small carps, body composition and 
blood parameters. At the end of testing, compared to 
control group, in the group containing 5 mL 100 g-1 
geranium root, a statistically significant difference was 
detected in leucocyte, hemoglobin and erythrocyte 
hemoglobin concentration levels (P < 0.01). However, 
as a result of the statistical analysis performed at the 
end of testing, no difference was found between con-
trol group and groups given geranium root extract in 
levels of erythrocyte, hematocrit, erythrocyte volume 
and erythrocyte hemoglobin (P > 0.05). 
Tunc and Patıroglu [23] evaluated the effective-
ness of PS extract which had both antiviral and im-
munomodulator efficiency for better symptoms during 
upper respiratory tract infection of patients followed 
up due to temporary hypogammaglobulinemia of suck-
ing babies. During pre and post treatment periods, no 
statistical difference was found between placebo group 
and the group given PS in terms of blood parameters 
[leucocyte, hemoglobin, thrombocyte, prothrombin 
time] (P < 0.05). 
Matthys and Heger [14] stated that, for patients 
believed to have an infectious disease, an increase in 
erythrocyte sedimentation rate appeared in patients 
using EPs®7630 liquid extract (10 out of 108 patients), 
placebo group patients (10 out of 109) and changes in 
leucocyte count appeared in patients using EPs®7630 
liquid extract (4 out of 108 patients), placebo group 
patients (5 out of 109). In this study, when the haema-
tological values (leucocyte, lymphocyte, monocyte, 
granulocyte, lymphocyte%, monocyte%, granulo-
cyte%, erythrocyte, hemoglobin, hematocrit, average 
cell volume, average cell hemoglobin, average cell 
hemoglobin concentration, platelet) in blood samples 
taken on day 14th (post treatment) from animals in test-
ing and control groups were comparatively examined, 
no statistical importance (P < 0.01 or P < 0.05) and 
difference was found between both groups. 
An acute cough is usually seen in viral infec-
tions (common cold) in respiratory systems. Sore 
throat, red nose, headache, body pain, fatigue and 
fever might also exist. Coughing reflections start due 
to damage on respiratory tract epithelium nerve sen-
sors or oscillation of inflammatory mediators. When 
Agbabiaka et al. [1] examined 5 studies performed in 
various years, they performed PS extracts as standard 
treatment for patients with acute bronchitis. They also 
included placebo group in the study. They compared 
a group on which PS extract was applied with another 
group on which antibiotics and acetylcysteine was not 
applied and 5 groups on which PS extract was applied 
with another group on which placebo was applied. In 
the study, they found that PS was effective in the group 
with acute bronchitis and acute bronchitis symptoms 
decreased significantly in these patients on day 7th. 
Tahan and Yaman [21] applied PS extract 
(EPs®7630) for 5 days on 61 children with asthma 
progressing due to upper respiratory tract viral in-
fections. In the study, fever and muscle pains in the 
group with PS treatment were statistically (P > 0.05) 
not found more important than in the group with no 
treatment and coughing frequency, nasal congestion 
and asthma attack cases in the group with PS treatment 
were statistically (P > 0.05) found more important 
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than in the group with no treatment. They stated that 
asthma attacks in the group with PS treatment were 
seen less frequently. 
Viruses, as the primary factor, are usually 
considered to be responsible for appearing respiratory 
tract infections and trigger asthma attacks. Increasing 
respiratory tract inflammations were the sudden reason 
of asthma attacks and respiratory tract inflammations in-
creasing during viral infections. As a result of decreasing 
the duration of viral infection efficiency, development of 
respiratory tract inflammations could be decreased and 
asthma attacks could be discarded [21]. Bao et al. [3] 
searched antitussive, secretolytic and anti-inflammatory 
effects of EPs®7630 in experimental animals. After the 
study, the coughing frequency of experimental animals 
with cough decreased significantly depending on the 
dosage and cough delay period became longer. Secre-
tolytic activity similarly decreased in rats. Lesions in 
lungs, trachea and bronch tissues caused by acute bacte-
rial bronchitis depending on EPs®7630 in rats regressed 
histopathologically. As a result, researchers were of the 
opinion that using EPs®7630 therapeutically in respira-
tory system infections was effective. For 7 days, Umca 
solution was applied as 3x30 drop/day for patients over 
18 years of age and showing acute bronchitis symptoms. 
Especially bronchitis severity score (BSS) [cough, mucus, 
dyspnea, chest pain while coughing, fever over 38.5°C] 
was determined for patients. At the end of the study, on 
day 7, BSS score decreased and individual symptoms 
decreased more distinctly than placebo group. On the 
fourth day of treatment applications, 69% of patients and 
33% of placebo group showed improvement [18]. 
Viruses are the most commonly seen factors in 
most of acute respiratory tract infections. Acute cough-
ing usually accompanies respiratory tract viral infec-
tions. Moreover, other symptoms such as sore throat, 
nasal flow, headache, joint pains, fatigue and fever can 
be seen [3]. In our study, in 10 Holstein calves in the 
control group, respiratory system symptoms (cough, 
fever, inappetency, serous nasal flow, drying on naso-
labial area, increase in respiration rate, foamy nasal 
flow and dyspnea) continued and decreased slightly. 
In 10 Holstein calves in the testing group, respiratory 
system symptoms decreased and got better. 
PS not only has an antiviral efficiency but also 
can increase immune response through secretory Ig A, 
IL-15, IL-6, IFN-ɣ ve TNF-α and shorten disease period 
[13]. Effects of PS on mucociliary system is believed 
to play a role in decreasing coughing frequency. The 
relation between EPs®7630 and cilia pulse frequency 
was searched in human cilia nose epithelial cell cultures. 
At the end of the study, EPs®7630 was thought to have 
increased cilia pulse frequency significantly depending 
on the dosage [16]. In conclusion, PS is thought to be 
effective through many mechanisms such as cilia func-
tions, immunoglobulins, cytokines and chemokines, 
phagocytic functions, intracell killing mechanisms and 
antiviral efficieny, to shorten viral upper respiratory tract 
infection period and to supress attack development by 
preventing inflammatory cases from progressing [7,22].
In this study, by using ELISA (IgG), antibody 
presence against BRSV was detected in Holstein calves 
aged 6 months and over showing symptoms of respira-
tory problems. Out of 20 BRSV seropositive calves, 
10 of them were classified as control group and the 
other ten as testing group. BRSV antibody titers were 
also detected in blood samples of both groups on day 
1st Umckaloabo/EPs®7630 liquid extract was given 
through oral route to animals in testing group according 
to their weights for 14 days morning, noon and night. 
No application was performed on animals in control 
group. BRSV antibody titers were detected in blood 
samples of animals in both groups taken on days 1st, 
3rd, 5th, 7th, 10th and 14th. 
In BRSV seropositive stock calves showing 
respiratory system symptoms, applying Umckaloabo/
EPs®7630 liquid extract helped antibody titer to increase 
and symptoms (cough, fever, inappetency, serous nasal 
flow, drying on nasolabial area, increase in respiration 
rate, foamy nasal flow and dyspnea) decreased. The in-
crease in antibody titers started from day 3th especially 
after applying Umckaloabo/EPs®7630 liquid extract. 
Besides, when haematological values in blood samples 
taken on day 14th from animals in testing and control 
groups were comparatively studied, no statistical differ-
ence was detected between both groups. During clinical 
observations, no side effect was observed either in test-
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